TG 02

Drug Profile

TG 02

Alternative Names: SB 1317; TG02

Latest Information Update: 07 Nov 2016

Price : $50

At a glance

  • Originator S*BIO
  • Developer S*BIO; Tragara Pharmaceuticals
  • Class Antineoplastics; Heterocyclic compounds with 4 or more rings; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Leukaemia; Multiple myeloma
  • Preclinical Solid tumours
  • No development reported Cancer

Most Recent Events

  • 27 Oct 2016 The National Cancer Institute plans a phase I/II trial for Glioblastoma and Anaplastic astrocytoma (Recurrent, Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02942264)
  • 01 May 2016 Tragara Pharmaceuticals completes a phase I trial in Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater) in USA (NCT01699152)
  • 01 Apr 2016 Tragara Pharmaceuticals completes a phase I trial in Leukaemia (Monotherapy, Second-line therapy or greater) and Multiple myeloma (Monotherapy, Combination therapy, Second-line therapy or greater) in USA (NCT01204164)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top